LT3445767T - Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui - Google Patents

Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui

Info

Publication number
LT3445767T
LT3445767T LTEP17720720.6T LT17720720T LT3445767T LT 3445767 T LT3445767 T LT 3445767T LT 17720720 T LT17720720 T LT 17720720T LT 3445767 T LT3445767 T LT 3445767T
Authority
LT
Lithuania
Prior art keywords
mcl
cancer
macrocyclic inhibitors
macrocyclic
inhibitors
Prior art date
Application number
LTEP17720720.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Alexander Hird
Matthew BELMONTE
Wenzhan YANG
John Secrist
Daniel Robbins
Steven KAZMIRSKI
Dedong Wu
Bo Peng
Jeffrey Johannes
Michelle Lamb
Qing Ye
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LT3445767T publication Critical patent/LT3445767T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP17720720.6T 2016-04-22 2017-04-21 Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui LT3445767T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326156P 2016-04-22 2016-04-22
PCT/EP2017/059511 WO2017182625A1 (en) 2016-04-22 2017-04-21 Macrocyclic mcl1 inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
LT3445767T true LT3445767T (lt) 2020-05-25

Family

ID=58664658

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17720720.6T LT3445767T (lt) 2016-04-22 2017-04-21 Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui

Country Status (37)

Country Link
US (4) US9840518B2 (OSRAM)
EP (1) EP3445767B1 (OSRAM)
JP (1) JP6894449B2 (OSRAM)
KR (1) KR102388208B1 (OSRAM)
CN (1) CN109071566B (OSRAM)
AR (1) AR108301A1 (OSRAM)
AU (1) AU2017252222B2 (OSRAM)
BR (1) BR112018070677B1 (OSRAM)
CL (1) CL2018002410A1 (OSRAM)
CO (1) CO2018008759A2 (OSRAM)
CR (1) CR20180499A (OSRAM)
CY (1) CY1123186T1 (OSRAM)
DK (1) DK3445767T3 (OSRAM)
DO (1) DOP2018000222A (OSRAM)
EA (1) EA036551B1 (OSRAM)
ES (1) ES2791319T3 (OSRAM)
HR (1) HRP20200673T1 (OSRAM)
HU (1) HUE049591T2 (OSRAM)
IL (1) IL262237B (OSRAM)
LT (1) LT3445767T (OSRAM)
MA (1) MA44721B1 (OSRAM)
ME (1) ME03729B (OSRAM)
MX (1) MX386103B (OSRAM)
NI (1) NI201800093A (OSRAM)
PE (1) PE20181803A1 (OSRAM)
PH (1) PH12018502227A1 (OSRAM)
PL (1) PL3445767T3 (OSRAM)
PT (1) PT3445767T (OSRAM)
RS (1) RS60257B1 (OSRAM)
SG (1) SG11201805838UA (OSRAM)
SI (1) SI3445767T1 (OSRAM)
SM (1) SMT202000249T1 (OSRAM)
SV (1) SV2018005742A (OSRAM)
TN (1) TN2018000319A1 (OSRAM)
TW (1) TWI742074B (OSRAM)
WO (1) WO2017182625A1 (OSRAM)
ZA (1) ZA201807766B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009408A (es) 2016-02-04 2018-11-09 Univ Johns Hopkins Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos.
CN108697701B (zh) 2016-02-04 2021-10-26 约翰霍普金斯大学 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CN109071566B (zh) 2016-04-22 2021-08-31 阿斯利康(瑞典)有限公司 用于治疗癌症的大环mcl-1抑制剂
CN109715632B (zh) 2016-05-19 2021-10-26 拜尔公开股份有限公司 大环吲哚衍生物
TWI781996B (zh) * 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成mcl-1抑制劑之方法
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
SG11202001182QA (en) 2017-08-15 2020-03-30 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
AU2018317836A1 (en) * 2017-08-15 2020-03-19 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
WO2019096914A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096907A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
US11478451B1 (en) 2017-11-17 2022-10-25 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
UY37971A (es) * 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos sustituidos
EP3710449B1 (en) 2017-11-17 2022-07-06 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
US20220041623A1 (en) * 2018-09-30 2022-02-10 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method thereof and application thereof in medicine
TWI810397B (zh) 2018-11-14 2023-08-01 瑞典商阿斯特捷利康公司 治療癌症之方法
CN111205309B (zh) * 2018-11-21 2023-04-07 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
US11691989B2 (en) 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
TWI760685B (zh) * 2019-01-23 2022-04-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑制劑的大環稠合的吡唑
MX2021010321A (es) * 2019-03-08 2021-11-17 Zeno Man Inc Compuestos macrociclicos.
CN113574058B (zh) * 2019-04-30 2024-04-16 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
CN114127059B (zh) 2019-05-10 2024-09-24 詹森生物科技公司 大环螯合剂及其使用方法
CN114127079A (zh) 2019-05-17 2022-03-01 布罗德研究所有限公司 制备大环吲哚的方法
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
US20220306653A1 (en) * 2019-06-21 2022-09-29 Janssen Pharmaceutica Nv Macrocyclic inhibitors of mcl-1
US20240067660A1 (en) 2019-07-09 2024-02-29 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
KR20220103984A (ko) * 2019-11-21 2022-07-25 얀센 파마슈티카 엔.브이. Mcl-1 억제제로서의 거대환식 인돌 유도체
MX2022006180A (es) * 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
AU2020409006A1 (en) * 2019-12-18 2022-06-30 Zeno Management, Inc. Macrocyclic compounds
AU2021222332A1 (en) 2020-02-21 2022-10-20 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as inhibitors of MCL-1
CN115335384B (zh) * 2020-03-30 2024-10-22 江苏恒瑞医药股份有限公司 一种吲哚类大环衍生物的结晶形式及其制备方法
CN115605486A (zh) * 2020-05-29 2023-01-13 詹森药业有限公司(Be) 作为mcl-1抑制剂的大环7-吡唑-5-基-吲哚衍生物
BR112022025631A2 (pt) 2020-06-19 2023-01-17 Janssen Pharmaceutica Nv Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1
WO2021255257A1 (en) 2020-06-19 2021-12-23 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
JP2023532592A (ja) 2020-07-08 2023-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1の阻害剤としての大環状エーテル含有インドール誘導体
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3200758A1 (en) 2020-12-17 2022-06-23 Janssen Pharmaceutica Nv Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
CN116848126A (zh) 2021-02-12 2023-10-03 詹森药业有限公司 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds
AU2022291381B2 (en) 2021-06-11 2025-04-24 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
CR20240553A (es) 2022-05-20 2025-05-02 Servier Lab Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101511074B1 (ko) * 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
DK2134685T3 (en) 2007-04-16 2015-12-07 Abbvie Inc 7-unsubstituted indole derivatives as MCL-1 inhibitors
PT2379580E (pt) * 2008-12-22 2014-01-20 Cubist Pharm Inc Novos agentes antibacterianos para o tratamento de infecções por bactérias gram positivas
CN102822163B (zh) * 2009-12-23 2016-01-20 艾恩伍德医药品股份有限公司 Crth2调节剂
PT2710018T (pt) * 2011-05-19 2022-03-01 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Compostos macrocíclicos como inibidores de proteína quinases
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
ES2654242T3 (es) * 2014-02-12 2018-02-12 Viiv Healthcare (No.5) Limited Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana
CN106456602B (zh) 2014-03-27 2020-11-24 范德比尔特大学 取代的吲哚mcl-1抑制剂
CU24399B1 (es) * 2014-04-11 2019-04-04 Bayer Pharma AG Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CN109071566B (zh) 2016-04-22 2021-08-31 阿斯利康(瑞典)有限公司 用于治疗癌症的大环mcl-1抑制剂

Also Published As

Publication number Publication date
HUE049591T2 (hu) 2020-09-28
AU2017252222B2 (en) 2019-11-07
CO2018008759A2 (es) 2018-09-20
PE20181803A1 (es) 2018-11-19
SI3445767T1 (sl) 2020-07-31
US20180155362A1 (en) 2018-06-07
DOP2018000222A (es) 2018-10-31
US9840518B2 (en) 2017-12-12
WO2017182625A1 (en) 2017-10-26
CY1123186T1 (el) 2021-10-29
MA44721A (fr) 2019-02-27
TWI742074B (zh) 2021-10-11
MX386103B (es) 2025-03-18
BR112018070677A2 (pt) 2019-02-05
NZ748173A (en) 2025-05-02
PH12018502227A1 (en) 2019-07-29
IL262237B (en) 2021-08-31
MX2018012711A (es) 2019-05-30
AR108301A1 (es) 2018-08-08
EA036551B1 (ru) 2020-11-23
SMT202000249T1 (it) 2020-07-08
ES2791319T3 (es) 2020-11-03
BR112018070677B1 (pt) 2024-02-06
TN2018000319A1 (en) 2020-01-16
MA44721B1 (fr) 2020-05-29
TW201803879A (zh) 2018-02-01
KR20180135030A (ko) 2018-12-19
US20210230184A1 (en) 2021-07-29
CA3020378A1 (en) 2017-10-26
CR20180499A (es) 2019-01-25
SV2018005742A (es) 2019-03-25
CN109071566A (zh) 2018-12-21
JP6894449B2 (ja) 2021-06-30
EA201892300A1 (ru) 2019-05-31
US11472816B2 (en) 2022-10-18
AU2017252222A1 (en) 2018-11-29
US20190185485A1 (en) 2019-06-20
PL3445767T3 (pl) 2020-07-13
SG11201805838UA (en) 2018-11-29
ME03729B (me) 2021-01-20
US10889594B2 (en) 2021-01-12
EP3445767B1 (en) 2020-02-19
US10196404B2 (en) 2019-02-05
IL262237A (en) 2018-11-29
KR102388208B1 (ko) 2022-04-18
CN109071566B (zh) 2021-08-31
PT3445767T (pt) 2020-05-13
RS60257B1 (sr) 2020-06-30
EP3445767A1 (en) 2019-02-27
CL2018002410A1 (es) 2018-12-07
US20170305926A1 (en) 2017-10-26
NI201800093A (es) 2019-03-14
JP2019514863A (ja) 2019-06-06
HRP20200673T1 (hr) 2020-07-10
DK3445767T3 (da) 2020-05-18
ZA201807766B (en) 2021-09-29

Similar Documents

Publication Publication Date Title
LT3445767T (lt) Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui
DK3728252T3 (da) 4-azaindolforbindelser
EP3664793A4 (en) MACROCYCLIC IMMUNOMODULATORS
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
LT3157916T (lt) Heteroarilo junginiai, skirti kinazės inhibavimui
HUE054784T2 (hu) 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
SI3319969T1 (sl) Diaril makrociklični polimorf
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3374359T3 (da) Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer
IL260082B (en) Small molecules against cancer
LT3402792T (lt) Chinolin-2-ono dariniai
LT3457851T (lt) Sobetiromo dariniai
BR112017001387A2 (pt) alargador.
BR112017001389A2 (pt) alargador.
LT3371168T (lt) Indolin-2-ono dariniai
EP3593139C0 (en) CANCER BIOMARKERS
BR112017001388A2 (pt) alargador.
BR112017001386A2 (pt) alargador.
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
LT3386997T (lt) Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
IT201600117182A1 (it) Ribobinatrice.